
PeptiDex Research
VerifiedIndependent researcher, not a medical professional
PeptiDex (independent)
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading peer-reviewed primary sources (PubMed/MEDLINE, ClinicalTrials.gov, FDA filings, EMA assessment reports) and synthesizing them into educational reference material with direct links so any reader can verify the underlying claims themselves.
The person behind PeptiDex Research is not a medical professional. Not a doctor, pharmacist, nurse practitioner, or any other licensed clinician. Nothing on this site is medical advice. Decisions about peptides — whether to use them, where to source them, dosing, cycle length, interactions, monitoring — must be made with a licensed physician who knows your individual medical history. PeptiDex cannot replace a clinician, cannot verify your individual safety, and cannot guarantee that any compound discussed is safe for human use. Most peptides covered on the site are research chemicals not approved by the FDA for human consumption.
What the site does well: it aggregates published literature on each compound, links every claim back to its primary source, grades evidence transparently (clinical trial vs. animal study vs. anecdotal), and discloses which vendors PeptiDex has affiliate relationships with. What the site explicitly does not do: provide medical advice, recommend protocols for individual readers, or vouch for any particular vendor's product safety beyond linking to their published Certificates of Analysis.
If you find an error or an outdated citation, the corrections page is the place to report it. Every correction is logged publicly with the original statement, the corrected statement, and the date of the change — the site does not silently overwrite substantive claims.
Specialties
Articles by PeptiDex Research (22)
Tirzepatide vs Semaglutide: Which is Better? A Complete Research Comparison
A head-to-head research comparison of tirzepatide vs semaglutide. We analyze the SURPASS and STEP clinical trials, mechanisms of action, side effects, and weight loss efficacy.
BPC-157 Dosage Guide: Complete Research Protocols for 2026
A comprehensive, evidence-based research guide to BPC-157 dosage protocols. We cover systemic vs local administration, reconstitution math, cycle lengths, and stacking.
Research Peptide Safety Explained: Purity, Protocols, and Risks in 2026
A comprehensive breakdown of research peptide safety. We analyze clinical safety profiles, the dangers of synthesis byproducts, and FDA regulatory actions.
Best Peptides for Muscle Growth: Research-Backed Guide for 2026
A research-backed comparison of the best peptides for muscle growth, including CJC-1295, Ipamorelin, MK-677, and IGF-1 LR3, based on clinical mechanism and safety.
Peptide Cycle Length: A Complete Research Guide for 2026
A comprehensive scientific guide to peptide cycle lengths. We explain receptor downregulation, angiogenic risks, and how to safely cycle BPC-157, TB-500, and secretagogues.
Best Peptide Stack for Injury Recovery in 2026: A Research Guide
A deep dive into the best peptide stacks for injury recovery. We analyze the synergistic effects of BPC-157, TB-500, and growth hormone secretagogues for tissue repair.
Best Peptides for Fat Loss in 2026: A Research Review
Comparing GLP-1 agonists, AOD-9604, Tesamorelin, and MOTS-c across clinical trials to determine the most effective peptide pathways for lipid oxidation.
How to Read a Peptide COA: A Complete 2026 Analytical Guide
A comprehensive guide on how to read a peptide Certificate of Analysis (COA). We explain HPLC purity, mass spectrometry, endotoxin testing, and how to spot forged documents.
Best Peptide Vendor 2026: Independently Reviewed & COA Verified
We independently evaluate peptide vendors based on third-party COA testing, purity verification, shipping speed, and pricing. Updated monthly for 2026.
Where to Buy Research Peptides Legally in 2026: A Complete Guide
A comprehensive guide on where to buy research peptides legally in 2026. We explain the regulatory landscape, FDA guidelines, and how to source verified peptides safely.
Tesamorelin: What Sets It Apart from Every Other Growth Hormone Peptide
A deep-dive comparison of Tesamorelin vs Sermorelin, CJC-1295, Ipamorelin, and MK-677. Covers FDA approval, visceral fat specificity, clinical evidence, and who Tesamorelin is actually best suited for.
Peptide Stacking in 2026: Why Combination Protocols Are Redefining Results
A deep dive into peptide stacking protocols — the Wolverine stack (BPC-157 & TB-500), growth hormone synergy (CJC-1295 & Ipamorelin), longevity and cognitive stacks, and how to combine compounds effectively.
The 2026 FDA Peptide Reclassification: What It Means for Patients, Providers, and the Future of Peptide Therapy
A comprehensive analysis of the 2026 FDA peptide reclassification — which 14 peptides are returning to Category 1, what it means for patients and providers, and how to navigate peptide therapy safely.
Retatrutide: The Triple-Agonist Peptide Explained
A comprehensive research guide to retatrutide — the first GLP-1/GIP/glucagon triple receptor agonist, its Phase 3 trial status, and what it means for the future of metabolic medicine.
MK-677 vs Ipamorelin: Which GH Secretagogue Is Better?
A research-backed comparison of MK-677 (ibutamoren) vs ipamorelin — oral vs injectable GH secretagogues compared on mechanism, side effects, and stacking.
CJC-1295 vs Sermorelin: GHRH Analog Comparison
A research-backed comparison of CJC-1295 and Sermorelin — two GHRH analogs for growth hormone optimization. DAC vs no-DAC, dosing, and clinical outcomes.
MOTS-c: The Mitochondrial Peptide for Energy & Metabolism
A deep dive into MOTS-c — the mitochondrial-derived peptide that mimics exercise, activates AMPK, and shows remarkable potential for metabolic regulation and longevity.
Oral Peptides vs Injectable Peptides: What You Need to Know
A research-backed comparison of oral vs injectable peptide delivery — bioavailability, SNAC technology, orforglipron, and the future of oral peptide formulations.
14 Peptides Are Going Legal Again in 2026: What the FDA Reclassification Means
The FDA is reclassifying 14 restricted peptides from Category 2 back to Category 1. What it means for patients, clinics, and the future of peptide therapy.
The Oral Peptide Revolution Has Arrived — And It Changes Everything
An independent analysis of the recent FDA approvals for oral GLP-1 and small-molecule peptide therapeutics, and what they mean for the future of longevity and weight loss.
GHK-Cu: The Breakout Peptide of 2026
An independent analysis of GHK-Cu, the copper tripeptide seeing a 1,000% surge in anti-aging, longevity, and skin regeneration research in 2026.
Ipamorelin vs CJC-1295: Stack Comparison Guide
Understanding the synergistic GHRP and GHRH relationship that maximizes endogenous growth hormone pulses without cortisol spikes.